Page 2410 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 146 Acute Coronary Syndromes 2151.e1

REFERENCES infarction treated with primary angioplasty: a meta-regression analysis of
randomized trials. Eur Heart J 30:2705, 2009.
1. White HD, Chew DP: Acute myocardial infarction. Lancet 372:570, 21. Steg PG, Bhatt DL, Hamm CW, et al: Effect of cangrelor on periproce-
2008. dural outcomes in percutaneous coronary interventions: a pooled analysis
2. Sami S, Willerson JT: Contemporary treatment of unstable angina and of patient-level data. Lancet 382:2013, 1981.
non-ST-segment-elevation myocardial infarction (part 1). Tex Heart Inst 22. Marchini JF, Manica A, Croce K: Stent thrombosis: Understanding and
J 37:141, 2010. managing a critical problem. Curr Treat Options Cardiovasc Med 14:91,
3. Sami S, Willerson JT: Contemporary treatment of unstable angina and 2012.
non-ST-segment-elevation myocardial infarction (part 2). Tex Heart Inst 23. Holmes MV, Perel P, Shah T, et al: CYP2C19 genotype, clopidogrel
J 37:262, 2010. metabolism, platelet function, and cardiovascular events: a systematic
4. Davi G, Patrono C: Platelet activation and atherothrombosis. N Engl J review and meta-analysis. JAMA 306:2704, 2011.
Med 357:2482, 2007. 24. Aster RH, Curtis BR, Bougie DW, et al: Thrombocytopenia associ-
5. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines ated with the use of GPIIb/IIIa inhibitors: position paper of the
for the management of patients with ST-elevation myocardial infarc- ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
tion: a report of the American College of Cardiology/American Heart J Thromb Haemost 4:678, 2006.
Association Task Force on Practice Guidelines (Committee to Revise the 25. Eikelboom JW, Weitz JI: New anticoagulants. Circulation 121:2010,
1999 Guidelines for the Management of Patients with Acute Myocardial 1523.
Infarction). Circulation 110:e82, 2004. 26. Mega JL, Braunwald E, Wiviott SD, et al: Rivaroxaban in patients with
6. Kushner FG, Hand M, Smith SC, Jr, et al: 2009 focused updates: ACC/ a recent acute coronary syndrome. N Engl J Med 366:9, 2011.
AHA guidelines for the management of patients with ST-elevation 27. Alexander JH, Lopes RD, James S, et al: Apixaban with antiplatelet
myocardial infarction (updating the 2004 Guideline and 2007 Focused therapy after acute coronary syndrome. N Engl J Med 365:699,
update) and ACC/AHA/SCAI guidelines on percutaneous coronary 2011.
intervention (updating the 2005 guideline and 2007 focused update): 28. Hirsh J, O’Donnell M, Eikelboom JW: Beyond unfractionated heparin
a report of the American College of Cardiology Foundation/American and warfarin: current and future advances. Circulation 116:552,
Heart Association Task Force on Practice Guidelines. Circulation 2007.
120:2271, 2009. 29. Eikelboom JW, Quinlan DJ, Mehta SR, et al: Unfractionated and low-
7. Indications for fibrinolytic therapy in suspected acute myocardial infarc- molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated
tion: collaborative overview of early mortality and major morbidity patients with ST-elevation acute myocardial infarction: a meta-analysis
results from all randomised trials of more than 1000 patients. Fibri- of the randomized trials. Circulation 112:3855, 2005.
nolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 343:311, 30. Collins R, MacMahon S, Flather M, et al: Clinical effects of antico-
1994. agulant therapy in suspected acute myocardial infarction: Systematic
8. Patel SC, Mody A: Cerebral hemorrhagic complications of thrombolytic overview of randomised trials. BMJ 313:652, 1996.
therapy. Prog Cardiovasc Dis 42:217, 1999. 31. Eikelboom JW, Anand SS, Malmberg K, et al: Unfractionated heparin
9. Mehta SR, Eikelboom JW, Yusuf S: Risk of intracranial haemorrhage and low-molecular-weight heparin in acute coronary syndrome without
with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet ST elevation: a meta-analysis. Lancet 355:1936, 2000.
356:449, 2000. 32. Yusuf S, Mehta SR, Xie C, et al: Effects of reviparin, a low-molecular-
10. Anderson JL, Adams CD, Antman EM, et al: ACCF/AHA focused weight heparin, on mortality, reinfarction, and strokes in patients with
update incorporated into the ACC/AHA 2007 guidelines for the man- acute myocardial infarction presenting with ST-segment elevation. JAMA
agement of patients with unstable angina/non-ST-elevation myocardial 293:427, 2005.
infarction: a report of the American College of Cardiology Foundation/ 33. Quinlan DJ, Eikelboom JW: Low-molecular-weight heparin as an
American Heart Association Task Force on Practice Guidelines. Circula- adjunct to thrombolysis in ST elevation myocardial infarction. Arch
tion 123(e426):2011, 2011. Intern Med 169:1163, 2009.
11. Patrono C, Garcia Rodriguez LA, Landolfi R, et al: Low-dose aspirin for 34. Yusuf S, Mehta SR, Chrolavicius S, et al: Effects of fondaparinux on
the prevention of atherothrombosis. N Engl J Med 353:2373, 2005. mortality and reinfarction in patients with acute ST-segment elevation
12. Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519,
of randomised trials of antiplatelet therapy for prevention of death, 2006.
myocardial infarction, and stroke in high risk patients. BMJ 324:71, 35. Yusuf S, Mehta SR, Chrolavicius S, et al: Comparison of fondaparinux
2002. and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464,
13. Mehta SR, Bassand JP, Chrolavicius S, et al: Dose comparisons of clopi- 2006.
dogrel and aspirin in acute coronary syndromes. N Engl J Med 363:930, 36. Steg PG, Jolly SS, Mehta SR, et al: Low-dose vs standard-dose unfrac-
2010. tionated heparin for percutaneous coronary intervention in acute
14. Chen ZM, Jiang LX, Chen YP, et al: Addition of clopidogrel to aspirin in coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8
45,852 patients with acute myocardial infarction: randomised placebo- randomized trial. JAMA 304:1339, 2010.
controlled trial. Lancet 366:2005, 1607. 37. Direct Thrombin Inhibitor Trialists’ Collaborative Group: Direct
15. Yusuf S, Zhao F, Mehta SR, et al: Effects of clopidogrel in addition to thrombin inhibitors in acute coronary syndromes: principal results of a
aspirin in patients with acute coronary syndromes without ST-segment meta-analysis based on individual patients’ data. Lancet 359:294, 2002.
elevation. N Engl J Med 345:494, 2001. 38. Stone GW, Witzenbichler B, Guagliumi G, et al: Bivalirudin during
16. Wiviott SD, Braunwald E, McCabe CH, et al: Prasugrel versus clopido- primary PCI in acute myocardial infarction. N Engl J Med 358:2218,
grel in patients with acute coronary syndromes. N Engl J Med 357:2007, 2008.
2001. 39. Steg PG, van ‘t Hof A, Hamm CW, et al: Bivalirudin started during
17. Roe MT, Armstrong PW, Fox KA, et al: Prasugrel versus clopidogrel emergency transport for primary PCI. N Engl J Med 369:2207,
for acute coronary syndromes without revascularization. N Engl J Med 2013.
367:1297, 2012. 40. Shahzad A, Kemp I, Mars C, et al: Unfractionated heparin versus bivali-
18. Wallentin L, Becker RC, Budaj A, et al: Ticagrelor versus clopidogrel in rudin in primary percutaneous coronary intervention (HEAT-PPCI): an
patients with acute coronary syndromes. N Engl J Med 361:1045, 2009. open-label, single centre, randomised controlled trial. Lancet 384:2014,
19. Boersma E, Harrington RA, Moliterno DJ, et al: Platelet glycoprotein 1849.
IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all 41. Han Y, Guo J, Zheng Y, et al: Bivalirudin vs heparin with or without
major randomised clinical trials. Lancet 359:189, 2002. tirofiban during primary percutaneous coronary intervention in acute
20. De LG, Navarese E, Marino P: Risk profile and benefits from Gp myocardial infarction: the BRIGHT randomized clinical trial. JAMA
IIb-IIIa inhibitors among patients with ST-segment elevation myocardial 313:1336, 2015.